Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) (SBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) trades at $6.29 (market cap $22.64B). The key difference: Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) is far larger — about 2.5× Kymera Therapeutics Inc. Common Stock's market cap, and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) pays a 0.52% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) for 1 Days on average.
| KYMR | SBS | |
|---|---|---|
Market Cap | $8.88B | $22.64B |
Volume | 1,028,790 | 8,795,741 |
Sector | Health | Utilities |
52-Week High | $127.31 | $7.08 |
52-Week Low | $55.80 | $4.46 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $8.27B | $29.44B |
Dividend Yield | — | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SBS trades at $6.45, down 4.16% today, with a P/E of 13.54 and a net income margin of 19.71%. Recent earnings showed a Q2 2026 miss after two prior beats. Technical indicators are mixed, with a bullish moving average signal but bearish oscillators. The company reported 2025 revenue of $38.09B and net income of $8.46B, though 2026 projections indicate a slight decline in profit margin to 19.71%.
The outlook is cautious; while valuation metrics appear reasonable and profitability is strong, recent earnings volatility and a negative net cash flow projection for 2026 pose risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited near-term upside potential amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares)
Sabesp provides water supply and sewage services in the Brazilian state of São Paulo. Its shares trade in Brazil as SBSP3 and in the U.S. as NYSE-listed ADSs under SBS.
Read more on SBS →
